774605-58-2

Basic information

• Product Name: 3-(2,6-Dichlorophenyl)-5-isopropylisoxazole-4-carboxylic acid
• Synonyms: 3-(2,6-Dichlorophenyl)-5-isopropylisoxazole-4-carboxylic acid;3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-isoxazolecarboxylic acid;Benzo[d]isoxazol-3-yl-acetic acid
• CAS NO: 774605-58-2
• Molecular Formula: C₁₃H₁₁Cl₂NO₃
• Molecular Weight: 300.13734
• Mol File: 774605-58-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-(2,6-Dichlorophenyl)-5-isopropylisoxazole-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2,6-Dichlorophenyl)-5-isopropylisoxazole-4-carboxylic acid(774605-58-2)
• EPA Substance Registry System: 3-(2,6-Dichlorophenyl)-5-isopropylisoxazole-4-carboxylic acid(774605-58-2)

Safety Data

• Hazardous Substances Data: 774605-58-2(Hazardous Substances Data)

Usage

General Description

3-(2,6-Dichlorophenyl)-5-isopropylisoxazole-4-carboxylic acid is a chemical compound with the molecular formula C13H10Cl2N2O3. It is an isoxazole derivative and a non-steroidal anti-inflammatory drug (NSAID). The compound is known to exhibit anti-inflammatory, analgesic, and antipyretic properties, making it useful in the treatment of various inflammatory conditions and pain management. It works by inhibiting the synthesis of prostaglandins, which are responsible for causing inflammation and pain. The compound is commonly used as an active ingredient in prescription and over-the-counter medications for the treatment of arthritis, menstrual pain, and other inflammatory conditions.

Upstream product

• 278597-28-7 methyl 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carboxylate 
• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 25185-95-9 2,6-dichlorobenzaldoxime 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 6579-27-7 2,6-Dichloro-N-hydroxybenzenecarboximidoyl chloride 
• 6575-28-6 (1E)-2,6-dichlorobenzaldehyde oxime 
• 7152-15-0 ethyl 4-methyl-3-oxo-pentanoate 
• 774605-35-5 ethyl 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carboxylate 

Relevant articles and documents

Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast

The nuclear farnesoid X receptor (FXR) and the enzyme soluble epoxide hydrolase (sEH) are validated molecular targets to treat metabolic disorders such as non-alcoholic steatohepatitis (NASH). Their simultaneous modulation in vivo has demonstrated a triad of anti-NASH effects and thus may generate synergistic efficacy. Here we report dual FXR activators/sEH inhibitors derived from the anti-asthma drug Zafirlukast. Systematic structural optimization of the scaffold has produced favorable dual potency on FXR and sEH while depleting the original cysteinyl leukotriene receptor antagonism of the lead drug. The resulting polypharmacological activity profile holds promise in the treatment of liver-related metabolic diseases.

Isoxazole carboxamide derivatives as ghrelin receptor modulators

The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.